The stock has a 36-month beta value of 1.69. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ARQT is 104.38M, and at present, short sellers hold a 18.94% of that float. On March 25, 2025, the average trading volume of ARQT was 2.31M shares.
ARQT) stock’s latest price update
The stock of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has increased by 0.09 when compared to last closing price of 17.29. Despite this, the company has experienced a 9.04% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-07 that Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) with prior inadequate response, intolerance, and contraindications to topical treatments New patient reported outcome data for investigational ZORYVE® (roflumilast) foam 0.3% demonstrated favorable efficacy, safety, and local tolerability data in scalp and body psoriasis In the United States, AD affects approximately 26 million adults and children and psoriasis affects approximately 9 million adults and children, with more than half experiencing involvement of the scalp WESTLAKE VILLAGE, Calif. and ORLANDO, Fla.
ARQT’s Market Performance
ARQT’s stock has risen by 9.04% in the past week, with a monthly rise of 39.67% and a quarterly rise of 22.64%. The volatility ratio for the week is 5.58% while the volatility levels for the last 30 days are 8.24% for Arcutis Biotherapeutics Inc The simple moving average for the past 20 days is 14.73% for ARQT’s stock, with a 53.83% simple moving average for the past 200 days.
Analysts’ Opinion of ARQT
Many brokerage firms have already submitted their reports for ARQT stocks, with H.C. Wainwright repeating the rating for ARQT by listing it as a “Buy.” The predicted price for ARQT in the upcoming period, according to H.C. Wainwright is $19 based on the research report published on December 30, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see ARQT reach a price target of $15. The rating they have provided for ARQT stocks is “Buy” according to the report published on August 28th, 2024.
Mizuho gave a rating of “Buy” to ARQT, setting the target price at $8 in the report published on January 03rd of the previous year.
ARQT Trading at 24.89% from the 50-Day Moving Average
After a stumble in the market that brought ARQT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.23% of loss for the given period.
Volatility was left at 8.24%, however, over the last 30 days, the volatility rate increased by 5.58%, as shares surge +42.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.63% upper at present.
During the last 5 trading sessions, ARQT rose by +9.33%, which changed the moving average for the period of 200-days by +117.69% in comparison to the 20-day moving average, which settled at $15.09. In addition, Arcutis Biotherapeutics Inc saw 24.23% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARQT starting from Watanabe Todd Franklin, who proposed sale 1,500 shares at the price of $17.52 back on Mar 24 ’25. After this action, Watanabe Todd Franklin now owns shares of Arcutis Biotherapeutics Inc, valued at $26,282 using the latest closing price.
Watanabe Todd Franklin, the insider of Arcutis Biotherapeutics Inc, sale 1,200 shares at $17.61 during a trade that took place back on Mar 17 ’25, which means that Watanabe Todd Franklin is holding 928,914 shares at $21,137 based on the most recent closing price.
Stock Fundamentals for ARQT
Current profitability levels for the company are sitting at:
- -0.65 for the present operating margin
- 0.9 for the gross margin
The net margin for Arcutis Biotherapeutics Inc stands at -0.71. The total capital return value is set at -0.48. Equity return is now at value -113.76, with -40.58 for asset returns.
Based on Arcutis Biotherapeutics Inc (ARQT), the company’s capital structure generated 0.41 points at debt to capital in total, while cash flow to debt ratio is standing at -1.01. The debt to equity ratio resting at 0.7. The interest coverage ratio of the stock is -4.73.
Currently, EBITDA for the company is -109.62 million with net debt to EBITDA at -0.36. When we switch over and look at the enterprise to sales, we see a ratio of 10.64. The receivables turnover for the company is 2.69for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.15.
Conclusion
To sum up, Arcutis Biotherapeutics Inc (ARQT) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
